IL6 and acute respiratory distress syndrome: The exacerbated production of IL-6 and other storm cytokines, where present, is considered among the leading causes of COVID-19/ARDS-related mortality, and therefore many clinical trials have been conducted targeting storm cytokines or their receptors, with inconsistent results, spurring controversial opinions on the use of systemic anti-inflammatory drugs (120).